02552.HK
Hua Medicine (Shanghai) Ltd.
HKSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
HKD 2.29
−3.17%Year over year
Reported trailing growth
- Revenue
- +415.7%
- EBITDA
- +53.3%
- EBIT
- +49.0%
- EPS
- +313.6%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- +132.0%
- EBITDA
- +562.9%
- EPS
- -4.6%
Three-year CAGR
- Revenue
- +201.0%
- EBITDA
- +68.3%
- EBIT
- +60.0%
- Net income
- +530.8%
- EPS
- +536.0%
- Free cash flow
- +85.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026